{
  "guideline": {
    "id": "PA166328676",
    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Celecoxib - CYP2C9",
    "objCls": "PGx Association",
    "source": "FDA",
    "version": 0,
    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328676",
    "relatedChemicals": [
      {
        "id": "PA448871",
        "name": "celecoxib",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166311941",
      "name": "Recommendation Annotation PA166311941",
      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448871",
          "name": "celecoxib",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216140,
        "html": "<p>&quot;Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in poor metabolizers with juvenile rheumatoid arthritis.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312641",
      "name": "Recommendation Annotation PA166312641",
      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448871",
          "name": "celecoxib",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452218940,
        "html": "<p>&quot;Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in poor metabolizers with juvenile rheumatoid arthritis.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311927",
      "name": "Recommendation Annotation PA166311927",
      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448871",
          "name": "celecoxib",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216126,
        "html": "<p>&quot;Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in poor metabolizers with juvenile rheumatoid arthritis.&quot;</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}